Eloxx Pharmaceuticals, Inc. (ELOX) Current Reports & Earnings Releases
| Filed | Form | Items | Filing |
|---|---|---|---|
| 2026-08-11 | 8-K | Results of Operations, Financial Statements & Exhibits | SEC |
| 2026-06-01 | 8-K | Unregistered Sales, Item 3.03, Officer / Director Changes, Charter Amendments, Financial Statements & Exhibits | SEC |
| 2026-05-01 | 8-K | Shareholder Vote Results | SEC |
| 2025-08-12 | 8-K | Officer / Director Changes, Financial Statements & Exhibits | SEC |
| 2024-10-17 | 8-K | Officer / Director Changes, Financial Statements & Exhibits | SEC |
| 2024-07-16 | 8-K | Material Agreement, Direct Financial Obligation | SEC |
| 2024-03-29 | 8-K | Officer / Director Changes | SEC |
| 2024-03-14 | 8-K | Material Agreement | SEC |
| 2024-01-09 | 8-K | Material Agreement, Unregistered Sales | SEC |
Sourced from SEC EDGAR 8-K/6-K filings. 8-K is the current-report form for US domestic issuers (Item 2.02 = earnings release); 6-K is the equivalent for foreign private issuers, including ADRs. Originals live on sec.gov.